American Diversified Holdings Corporation (ADHC) Completes Acquisition Of GlucoGuard, a AI-Based Medical Device for Managing Nocturnal Hypoglycemia in Diabetic Patients

Rhea-AI Summary

American Diversified Holdings (ADHC) has completed the acquisition of GlucoGuard, an AI-driven medical device technology from IMD Solutions. GlucoGuard is designed to manage nocturnal hypoglycemia in diabetic patients through non-invasive, continuous glucose monitoring and delivery. The acquisition terms are undisclosed, but financing is expected to be non-dilutive.

Key developments include:

• Elimination of $2.7 million in corporate debt
• 144 million share cancellation in progress
• Filed fiscal year-end financials
• Global distribution of corporate information

GlucoGuard's founder, Zachary Smith, will join ADHC's advisory board. The technology is being developed in collaboration with a leading U.S. research university, a biomedical and defense engineering firm, and a top publicly traded company in the CGM sector.

Positive

• Acquisition of GlucoGuard, an innovative AI-driven medical device for managing nocturnal hypoglycemia
• Elimination of $2.7 million in corporate debt, creating a debt-free company
• 144 million share cancellation in progress, potentially increasing shareholder value
• Collaboration with key partners in research, engineering, and CGM sectors for GlucoGuard development
• Non-dilutive financing expected for the acquisition

Negative

• None.

Del Mar, California--(Newsfile Corp. - September 30, 2024) - American Diversified Holdings Corporation (OTC Pink: ADHC) is pleased to announce the completion of the previously announced acquisition of GlucoGuard, a revolutionary AI-driven medical device technology from IMD Solutions, Phoenix, AZ. GlucoGuard is designed to address the critical challenge of managing nocturnal Hypoglycemia for diabetic patients, offering a breakthrough in non-invasive, continuous glucose monitoring and delivery.

Other recent developments are underway that are extremely beneficial in ADHC capitalization structure paving the way for enhancing shareholder value.

• Elimination of $2.7 mm in Corporate Debt creating a "DEBT FREE" company.
• 144 Million Share Cancellation is underway via the legal process.
• Fiscal Year End Financials have been filed with OTC markets. (Period Ending 7-31-24).
• Global Distribution of ADHC's Corporate Information is Underway, including Europe, Asia, North and South America.

Share Holders can expect many exciting and transformative updates to be released soon.

COMPANY OVERVIEW

In addition to the completed acquisition, GlucoGuard's founder, Zachary Smith, BS/MS Biomedical Engineering (Arizona State University), will join ADHC's advisory board. Smith will work alongside Bill Colone, a renowned expert in biomedical solutions, to advance GlucoGuard's development and integration into ADHC's expanding healthcare technology portfolio.

The terms of the acquisition remain undisclosed, but financing is expected to be non-dilutive.

Transforming Diabetes Management
Zachary Smith commented, "ADHC provides the ideal platform for the commercialization of GlucoGuard. Both Bill and I are eager to bring this life-saving technology to market, helping millions of diabetic patients-both adults and children-better manage their glucose levels with greater safety and ease."

Bill Colone added, "Hypoglycemia, particularly during sleep, is a persistent and dangerous issue for diabetic patients, often leading to serious consequences like the dreaded 'Death in Bed' syndrome. GlucoGuard's technology offers a game-changing solution to this pressing problem."

Key Development Partnerships
The GlucoGuard system is being developed in collaboration with three key partners:

1. A leading U.S. research university.
2. A highly respected biomedical and defense engineering firm.
3. A top publicly traded company in the Continuous Glucose Monitoring (CGM) sector.

Further details on these collaborations will be disclosed soon.

Cutting-Edge Technology for Unmet Medical Needs
GlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal Hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effective glucose management without disturbing the patient's rest.

"The GlucoGuard invention is a significant leap forward in addressing one of the most dangerous complications of diabetes," said ADHC management. "We are thrilled to welcome Zachary Smith and his innovative team to ADHC, and we're committed to fast-tracking the development and commercialization of this much-needed technology."

About Artificial Intelligence and Health Care
A recent report from the Mayo Clinic identified three potential benefits of AI in healthcare:

1. Improving outcomes for both patients and clinical teams.
2. Lowering healthcare costs.
3. Benefitting population health.

From preventive screenings to diagnosis and treatment, AI is being used throughout the continuum of care today. Two examples are Preventive Health Care and Risk Assessment.

Cancer Screenings that use radiology can leverage AI to help produce results faster. A noted example is analyzing kidney images in a laborious 45 minute process. AI automated process can reduce this analysis to minutes, saving time, money and giving a more accurate diagnosis.

Pre-diabetes patients with no notable symptoms can be screened using AI to determine which type of diabetes they are at risk for and begin preventative care.

See AI in healthcare: The future of patient care and health management - Mayo Clinic Press.

About the Diabetes Market
The diabetes market is poised for substantial growth, with the U.S. market valued at $28 billion, underscoring the vast potential for GlucoGuard's adoption.

For more information on the $28 billion diabetes market, visit: United States Diabetes Market Report.

The Continuous Glucose Monitoring (CGM) sector, valued at $6.8 billion, further emphasizes the critical demand for advanced glucose management solutions.

For details on the CGM market, visit: Continuous Glucose Monitoring Market.

Image 1

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/224435_0235dd85640e0901_001full.jpg

About IMD Solutions, Inc.
IMD Solutions, Inc. is a Nevada-based medical device company developing GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, IMD Solutions is at the forefront of diabetes management technology.

For more information, visit: www.GlucoGuardSleep.com.
Contact: Phone: 817-525-0057
Email: info@GlucoGuardSleep.com

Image 2

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/224435_0235dd85640e0901_002full.jpg

About AMERICAN DIVERSIFIED HOLDINGS CORPORATION
www.UniversalWellnessAI.com
www.UniversalWellnessShop.com

John Cacchioli, CEO
American Diversified Holdings Corporation
Telephone: (212) 537-5900
Email: JC@American-Diversified.com

Social Media:
TWITTER: @ADHCManagement.
This Twitter page is the only official Twitter page for ADHC.

SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/224435

FAQ

What is the purpose of ADHC's acquisition of GlucoGuard?

ADHC acquired GlucoGuard to expand its healthcare technology portfolio with an innovative AI-driven medical device designed to manage nocturnal hypoglycemia in diabetic patients through non-invasive, continuous glucose monitoring and delivery.

How will the GlucoGuard acquisition impact ADHC's financial structure?

The acquisition's financing is expected to be non-dilutive, and ADHC has eliminated $2.7 million in corporate debt, becoming debt-free. Additionally, a 144 million share cancellation is in progress, potentially enhancing shareholder value.

Who are the key partners in developing GlucoGuard for ADHC?

GlucoGuard is being developed in collaboration with a leading U.S. research university, a respected biomedical and defense engineering firm, and a top publicly traded company in the Continuous Glucose Monitoring (CGM) sector.

What is the technology behind ADHC's GlucoGuard device?

GlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring. It uses a mouthpiece to continuously monitor glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected, using sophisticated AI algorithms.